Basaglar is manufactured by Eli Lilly and Company [1].
Who makes Basaglar and what is it?
Eli Lilly and Company manufactures Basaglar, which is a brand name for insulin glargine [1][2]. It is a long-acting insulin used to control high blood sugar in adults and children with diabetes mellitus [2].
When does Basaglar's patent expire?
Information regarding the specific patent expiry dates for Basaglar is not readily available in the provided context. Patent and exclusivity information for pharmaceuticals is complex and can involve multiple patents, each with different expiry dates, and may also be subject to legal challenges. For detailed patent information, resources like DrugPatentWatch.com would be necessary [3].
How does Basaglar compare to other insulins?
Basaglar is a biosimilar to Lantus, another long-acting insulin glargine product [2][4]. Biosimilars are highly similar to already approved biological medicines, with no clinically meaningful differences in terms of safety, purity, and potency [5]. Patients and healthcare providers may consider biosimilars as therapeutic alternatives to their reference products, often with potential cost savings [5].
What is the mechanism of action for Basaglar?
As insulin glargine, Basaglar works by lowering blood glucose. It mimics the action of endogenous insulin by acting as a peripheral glucose-lowering agent. It stimulates glucose uptake in peripheral tissues like skeletal muscle and fat, and it also inhibits hepatic glucose production [2].